Please Wait...

Independent, Centralized Image Review and Analyses Supporting Development of VK2809 to Treat NAFLD/NASH

Non-alcoholic fatty liver disease (NAFLD), and its progression to non-alcoholic steatohepatitis (NASH), is estimated to become the most common chronic liver condition in Western populations. However, the etiology of NAFLD/NASH is not well understood, and, despite many Phase III trials, a drug has not yet been approved for treatment. Therefore, ongoing research is essential. Clinical medical imaging can be an effective tool to appropriately confirm patient eligibility and monitor treatment efficacy in NAFLD/NASH drug development. Further, independent central review and analyses of medical images can ensure high-quality results throughout the duration of the trial.

Download our case study to learn how advanced medical imaging played an important role during the clinical trial conducted by Viking Therapeutics to evaluate VK2809 for the treatment of patients with biopsy-proven NASH with fibrosis.



Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Attending #SCOPE2020? Kevin Bishop, Bioclinica's VP of RTSM, will be speaking about novel clinical trial designs an…
Bioclinica (4 days ago)
As #clinicaltrial designs evolve, trial supply management becomes increasingly complex. Adaptive protocols, direct-…
Bioclinica (6 days ago)
#Clinicaltrials are not only more expensive and more complex, they also take longer than ever to execute. Since man…
Bioclinica (2 weeks ago)
#CTMS is integral to #clinicaltrials, but it can be resource-intensive. That's why we created Bioclinica CTMS Direc…
Bioclinica (2 weeks ago)
Going to SCOPE? Visit Bioclinica at booth 404! #SCOPE2020
Bioclinica (3 weeks ago)
In case you missed it: Bioclinica announces additions to Software Solutions leadership. We welcome Guy Crossley, Ri…
Bioclinica (6 weeks ago)